The effectiveness of nivolumab, a checkpoint inhibitor medication, on enhancing the survival chances of individuals diagnosed with relapsed classical Hodgkin lymphoma, utilizing a thorough meta-analysis of clinical trial

The effectiveness of nivolumab, a checkpoint inhibitor medication, on enhancing the survival chances of individuals diagnosed with relapsed classical Hodgkin lymphoma, utilizing a thorough meta-analysis of clinical trial. This research investigates the potential benefits of using nivolumab, a PD۱-blocking antibody, to enhance the survival prospects of individuals suffering from Hodgkin's lymphoma, especially those whose condition has recurred or become unresponsive to conventional treatments. The significance of this investigation lies in exploring how nivolumab, known for its effectiveness in boosting treatment outcomes for solid tumors, could similarly benefit patients with Hodgkin's lymphoma.

کلیدواژه ها:

Checkpoint inhibitor ، Nivolumab ، Hodgkin lymphoma ، PD۱ blockade